Effects of pre-exposure prophylaxis
for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis.
"A Latent Class Analysis of Risk Factors for Acquiring HIV among Men Who Have Sex with Men: Implications for Implementing Pre-Exposure Prophylaxis
Programs." AIDS Patient Care and STDs 29 (11): 597-605.
Values and preferences on the use of oral Pre-exposure Prophylaxis
(PrEP) for HIV prevention among multiple populations: A systematic review of the literature.
Modelling estimates that, globally, 20-25% reductions in HIV incidence among men who have sex with men could be achieved through pre-exposure prophylaxis
, averting up to 1 million new infections among this group over 10 years.
In one of these studies, the iPrEX trial, daily use of Truvada as pre-exposure prophylaxis
(PrEP) reduced sexual HIV acquisition by 44% in a population of gay men, other men who have sex with men (MSM) and transgender women who have sex with men--all of whom were at high risk of HIV (1).
ACARP intends to vaccinate 70 percent of dogs in the country through strategic components: setting priority vaccination areas, protecting program implementers by giving pre-exposure prophylaxis
(PEP), large-scale information dissemination, and partnerships with private local and international organizations such as the World Organization for Animal Health (OIE) and Global Alliance for Rabies Control (GARC).
The stories and narratives in this issue include a young feminist's experience working in an abortion clinic and her call for us to trust and honor women; a woman's telling description of being shackled, humiliated, and dehumanized during pregnancy and childbirth when she was incarcerated; and a conversation about a woman's journey to conceive a child with her HIV-positive partner using Pre-Exposure Prophylaxis
HIV-negative volunteers who took a daily dose of the antiretroviral medicine tenofovir as oral pre-exposure prophylaxis
(PrEP) were 49% less likely to become infected with HIV than the volunteers who took the placebo.
(1) Recently, the field of HIV prevention has gathered positive results from different strategies, among different populations, and with varying effect sizes, including the treatment of HIV-positive women and men in discordant couples, (2-4) male circumcision of HIV-negative men in sub-Saharan Africa, (5-7) a HIV vaccine evaluated in a community-based trial among HIV-negative men and women in Thailand, (8) the use of vaginal gel formulation of TDF for HIV prevention in women in South Africa, (9) pre-exposure prophylaxis
(PrEP) with tenofovir disoproxil fumarate (TDF) or emtricitabine and TDF (TDF-FTC) among HIV-1-serodiscordant heterosexual couples from Kenya and Uganda, (10) and PrEP with TDF-FTC among heterosexual men and women in Africa.
Grant is the protocol chair for the Pre-Exposure Prophylaxis
Initiative (iPrEx) trial, (1) the first placebo-controlled trial to demonstrate partial protection from HIV infection with oral preexposure prophylaxis (PrEP).
The United States Food and Drug Administration (FDA) has registered Truvada for pre-exposure prophylaxis
for men and women.
The guidance is based on clinical trials indicating that HIV-negative people taking a daily dose of oral antiretroviral medication, known as pre-exposure prophylaxis
(PrEP), to reduce the risk of infection, is both safe for people to use and effective in preventing HIV.